Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma

Elizabeth Jacobs, Maria Elena Martinez, Julie Buckmeier, Peter Lance, Melissa May, Peter Jurutka

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Fibroblast growth factor-23 (FGF-23) is a phosphaturic peptide and a key component of an endocrine feedback loop along with the hormonal vitamin D metabolite 1,25(OH) 2 D. Vitamin D has been shown to be inversely related to colorectal neoplasia; therefore, we hypothesized that the effect of FGF-23 on vitamin D metabolite concentrations could have implications for the risk of colorectal neoplasia. Materials and Methods: The purpose of this study was to prospectively evaluate the association between circulating concentrations of FGF-23 and the risk of metachronous (recurrent) colorectal adenomas. FGF-23 levels were assessed in 100 male and female participants from the Ursodeoxycholic Acid Trial, 50 of whom had a metachronous colorectal adenoma and 50 who did not. Results: Compared to the lowest tertile of FGF-23, the adjusted odds ratios (95% CIs) for the second and third tertiles were 2.80 (0.94 to 8.31) and 3.41 (1.09 to 10.67), respectively (P-trend=.03). In a linear regression model, there was also a statistically significant inverse relationship between FGF-23 and 1,25(OH) 2 D (β-coefficient=-1. 2; P=.001). In contrast, no statistically significant trend was observed between FGF-23 and 25(OH)D concentrations (β-coefficient=0.55; P=.10). Conclusions: The current work presents novel preliminary evidence of a relationship between FGF-23 and the risk for colorectal neoplasia. FGF-23 activity may be mediated through biologic effects on individual serum and colonic 1,25(OH) 2 D levels, or it may be independent from the vitamin D pathway. Further studies in larger populations are necessary for confirmation and expansion of these hypothesis-generating results.

Original languageEnglish (US)
Article number3
JournalJournal of Carcinogenesis
Volume10
DOIs
StatePublished - 2011

Fingerprint

Adenoma
Vitamin D
Linear Models
fibroblast growth factor 23
Fibroblast Growth Factor 1
Ursodeoxycholic Acid
Neoplasms
Odds Ratio
Peptides
Serum
Population

Keywords

  • Adenoma
  • cancer
  • colorectal
  • fibroblast growth factor
  • fibroblast growth factor-23

ASJC Scopus subject areas

  • Cancer Research
  • Health, Toxicology and Mutagenesis
  • Oncology

Cite this

Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma. / Jacobs, Elizabeth; Martinez, Maria Elena; Buckmeier, Julie; Lance, Peter; May, Melissa; Jurutka, Peter.

In: Journal of Carcinogenesis, Vol. 10, 3, 2011.

Research output: Contribution to journalArticle

Jacobs, Elizabeth ; Martinez, Maria Elena ; Buckmeier, Julie ; Lance, Peter ; May, Melissa ; Jurutka, Peter. / Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma. In: Journal of Carcinogenesis. 2011 ; Vol. 10.
@article{e0339fb7c85b4c8183ec077cc75fb645,
title = "Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma",
abstract = "Background: Fibroblast growth factor-23 (FGF-23) is a phosphaturic peptide and a key component of an endocrine feedback loop along with the hormonal vitamin D metabolite 1,25(OH) 2 D. Vitamin D has been shown to be inversely related to colorectal neoplasia; therefore, we hypothesized that the effect of FGF-23 on vitamin D metabolite concentrations could have implications for the risk of colorectal neoplasia. Materials and Methods: The purpose of this study was to prospectively evaluate the association between circulating concentrations of FGF-23 and the risk of metachronous (recurrent) colorectal adenomas. FGF-23 levels were assessed in 100 male and female participants from the Ursodeoxycholic Acid Trial, 50 of whom had a metachronous colorectal adenoma and 50 who did not. Results: Compared to the lowest tertile of FGF-23, the adjusted odds ratios (95{\%} CIs) for the second and third tertiles were 2.80 (0.94 to 8.31) and 3.41 (1.09 to 10.67), respectively (P-trend=.03). In a linear regression model, there was also a statistically significant inverse relationship between FGF-23 and 1,25(OH) 2 D (β-coefficient=-1. 2; P=.001). In contrast, no statistically significant trend was observed between FGF-23 and 25(OH)D concentrations (β-coefficient=0.55; P=.10). Conclusions: The current work presents novel preliminary evidence of a relationship between FGF-23 and the risk for colorectal neoplasia. FGF-23 activity may be mediated through biologic effects on individual serum and colonic 1,25(OH) 2 D levels, or it may be independent from the vitamin D pathway. Further studies in larger populations are necessary for confirmation and expansion of these hypothesis-generating results.",
keywords = "Adenoma, cancer, colorectal, fibroblast growth factor, fibroblast growth factor-23",
author = "Elizabeth Jacobs and Martinez, {Maria Elena} and Julie Buckmeier and Peter Lance and Melissa May and Peter Jurutka",
year = "2011",
doi = "10.4103/1477-3163.76723",
language = "English (US)",
volume = "10",
journal = "Journal of Carcinogenesis",
issn = "0974-6773",
publisher = "Medknow Publications and Media Pvt. Ltd",

}

TY - JOUR

T1 - Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma

AU - Jacobs, Elizabeth

AU - Martinez, Maria Elena

AU - Buckmeier, Julie

AU - Lance, Peter

AU - May, Melissa

AU - Jurutka, Peter

PY - 2011

Y1 - 2011

N2 - Background: Fibroblast growth factor-23 (FGF-23) is a phosphaturic peptide and a key component of an endocrine feedback loop along with the hormonal vitamin D metabolite 1,25(OH) 2 D. Vitamin D has been shown to be inversely related to colorectal neoplasia; therefore, we hypothesized that the effect of FGF-23 on vitamin D metabolite concentrations could have implications for the risk of colorectal neoplasia. Materials and Methods: The purpose of this study was to prospectively evaluate the association between circulating concentrations of FGF-23 and the risk of metachronous (recurrent) colorectal adenomas. FGF-23 levels were assessed in 100 male and female participants from the Ursodeoxycholic Acid Trial, 50 of whom had a metachronous colorectal adenoma and 50 who did not. Results: Compared to the lowest tertile of FGF-23, the adjusted odds ratios (95% CIs) for the second and third tertiles were 2.80 (0.94 to 8.31) and 3.41 (1.09 to 10.67), respectively (P-trend=.03). In a linear regression model, there was also a statistically significant inverse relationship between FGF-23 and 1,25(OH) 2 D (β-coefficient=-1. 2; P=.001). In contrast, no statistically significant trend was observed between FGF-23 and 25(OH)D concentrations (β-coefficient=0.55; P=.10). Conclusions: The current work presents novel preliminary evidence of a relationship between FGF-23 and the risk for colorectal neoplasia. FGF-23 activity may be mediated through biologic effects on individual serum and colonic 1,25(OH) 2 D levels, or it may be independent from the vitamin D pathway. Further studies in larger populations are necessary for confirmation and expansion of these hypothesis-generating results.

AB - Background: Fibroblast growth factor-23 (FGF-23) is a phosphaturic peptide and a key component of an endocrine feedback loop along with the hormonal vitamin D metabolite 1,25(OH) 2 D. Vitamin D has been shown to be inversely related to colorectal neoplasia; therefore, we hypothesized that the effect of FGF-23 on vitamin D metabolite concentrations could have implications for the risk of colorectal neoplasia. Materials and Methods: The purpose of this study was to prospectively evaluate the association between circulating concentrations of FGF-23 and the risk of metachronous (recurrent) colorectal adenomas. FGF-23 levels were assessed in 100 male and female participants from the Ursodeoxycholic Acid Trial, 50 of whom had a metachronous colorectal adenoma and 50 who did not. Results: Compared to the lowest tertile of FGF-23, the adjusted odds ratios (95% CIs) for the second and third tertiles were 2.80 (0.94 to 8.31) and 3.41 (1.09 to 10.67), respectively (P-trend=.03). In a linear regression model, there was also a statistically significant inverse relationship between FGF-23 and 1,25(OH) 2 D (β-coefficient=-1. 2; P=.001). In contrast, no statistically significant trend was observed between FGF-23 and 25(OH)D concentrations (β-coefficient=0.55; P=.10). Conclusions: The current work presents novel preliminary evidence of a relationship between FGF-23 and the risk for colorectal neoplasia. FGF-23 activity may be mediated through biologic effects on individual serum and colonic 1,25(OH) 2 D levels, or it may be independent from the vitamin D pathway. Further studies in larger populations are necessary for confirmation and expansion of these hypothesis-generating results.

KW - Adenoma

KW - cancer

KW - colorectal

KW - fibroblast growth factor

KW - fibroblast growth factor-23

UR - http://www.scopus.com/inward/record.url?scp=79960338678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960338678&partnerID=8YFLogxK

U2 - 10.4103/1477-3163.76723

DO - 10.4103/1477-3163.76723

M3 - Article

C2 - 21383962

AN - SCOPUS:79960338678

VL - 10

JO - Journal of Carcinogenesis

JF - Journal of Carcinogenesis

SN - 0974-6773

M1 - 3

ER -